A Concise Review on Effect of PEGylation on the Properties of Lipid-Based Nanoparticles.

IF 1.6 4区医学 Q4 BIOCHEMICAL RESEARCH METHODS

Assay and drug development technologies Pub Date : 2024-07-01 Epub Date: 2024-06-03 DOI:10.1089/adt.2024.015

Janesha Krishnan, Praveena Poomalai, Ashwin Ravichandran, Aishwarya Reddy, Raman Sureshkumar

{"title":"A Concise Review on Effect of PEGylation on the Properties of Lipid-Based Nanoparticles.","authors":"Janesha Krishnan, Praveena Poomalai, Ashwin Ravichandran, Aishwarya Reddy, Raman Sureshkumar","doi":"10.1089/adt.2024.015","DOIUrl":null,"url":null,"abstract":"\n Nanoparticle-based drug delivery systems have emerged as promising platforms for enhancing therapeutic efficacy while minimizing off-target effects. Among various strategies employed to optimize these systems, polyethylene glycol (PEG) modification, known as PEGylation-the covalent attachment of PEG to nanoparticles, has gained considerable attention for its ability to impart stealth properties to nanoparticles while also extending circulation time and improving biocompatibility. PEGylation extends to different drug delivery systems, in specific, nanoparticles for targeting cancer cells, where the concentration of drug in the cancer cells is improved by virtue of PEGylation. The primary challenge linked to PEGylation lies in its confirmation. Numerous research findings provide comprehensive insights into selecting PEG for various PEGylation methods. In this review, we have endeavored to consolidate the outcomes concerning the choice of PEG and diverse PEGylation techniques.\n ","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":"246-264"},"PeriodicalIF":1.6000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Assay and drug development technologies","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/adt.2024.015","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/3 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}

引用次数: 0

Abstract

Nanoparticle-based drug delivery systems have emerged as promising platforms for enhancing therapeutic efficacy while minimizing off-target effects. Among various strategies employed to optimize these systems, polyethylene glycol (PEG) modification, known as PEGylation-the covalent attachment of PEG to nanoparticles, has gained considerable attention for its ability to impart stealth properties to nanoparticles while also extending circulation time and improving biocompatibility. PEGylation extends to different drug delivery systems, in specific, nanoparticles for targeting cancer cells, where the concentration of drug in the cancer cells is improved by virtue of PEGylation. The primary challenge linked to PEGylation lies in its confirmation. Numerous research findings provide comprehensive insights into selecting PEG for various PEGylation methods. In this review, we have endeavored to consolidate the outcomes concerning the choice of PEG and diverse PEGylation techniques.

查看原文本刊更多论文

PEG 化对脂基纳米粒子特性影响的简明综述。

以纳米颗粒为基础的给药系统已成为既能提高疗效又能最大限度减少脱靶效应的理想平台。在优化这些系统所采用的各种策略中，聚乙二醇（PEG）修饰（即 PEG 化--PEG 与纳米颗粒的共价连接）因其能够赋予纳米颗粒隐形特性，同时延长流通时间并改善生物相容性而备受关注。PEG 乙基化可扩展到不同的给药系统，特别是用于靶向癌细胞的纳米颗粒，通过 PEG 乙基化可提高癌细胞中的药物浓度。与 PEG 化相关的主要挑战在于其确认。大量研究成果为各种 PEG 化方法选择 PEG 提供了全面的见解。在本综述中，我们将努力整合有关 PEG 选择和各种 PEG 化技术的成果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Assay and drug development technologies 医学-生化研究方法

CiteScore

3.60

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： ASSAY and Drug Development Technologies provides access to novel techniques and robust tools that enable critical advances in early-stage screening. This research published in the Journal leads to important therapeutics and platforms for drug discovery and development. This reputable peer-reviewed journal features original papers application-oriented technology reviews, topical issues on novel and burgeoning areas of research, and reports in methodology and technology application. ASSAY and Drug Development Technologies coverage includes: -Assay design, target development, and high-throughput technologies- Hit to Lead optimization and medicinal chemistry through preclinical candidate selection- Lab automation, sample management, bioinformatics, data mining, virtual screening, and data analysis- Approaches to assays configured for gene families, inherited, and infectious diseases- Assays and strategies for adapting model organisms to drug discovery- The use of stem cells as models of disease- Translation of phenotypic outputs to target identification- Exploration and mechanistic studies of the technical basis for assay and screening artifacts